MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd. (MDWD) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (2.9) | D+ (1.8) | B- (2.9) | C (2.3) | C+ (2.6) | C+ (2.5) |
| 2026-11-06 | B- (2.9) | D+ (1.8) | B- (2.9) | C (2.3) | C+ (2.7) | C+ (2.5) |
| 2026-10-30 | B- (2.9) | D+ (1.7) | B- (2.9) | C (2.4) | C+ (2.7) | C+ (2.5) |
| 2026-10-23 | B- (2.9) | D+ (1.7) | B- (2.9) | C- (2.1) | C+ (2.6) | C (2.5) |
| 2026-10-16 | B- (2.9) | D+ (1.7) | B- (2.9) | C- (2.0) | C+ (2.6) | C (2.5) |